ASM in-licenses cancer compound

Antisoma (LSE:ASM; NASD-EU:ASOM) in-licensed a vascular targeting agent, DMXAA (5,6-dimethylxanthenone-4-acetic acid), from Cancer Research Ventures (London, U.K.), the Cancer Research Campaign's tech...